Siponimod + AlemtuzumabUnknown
Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with MAYZENT after alemtuzumab is not recommended.
Source: FDA drug label - siponimod
Brand names: Mayzent
Sphingosine 1-phosphate Receptor Modulator · Sphingosine 1-Phosphate Receptor Modulators
2 interactions on record
Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with MAYZENT after alemtuzumab is not recommended.
Source: FDA drug label - siponimod
Class Ia (e.g., quinidine, procainamide) and Class III (e.g., amiodarone, sotalol) antiarrhythmic drugs have been associated with cases of Torsades de Pointes in patients with bradycardia.
Source: FDA drug label - siponimod